WO2008111630A1 - ピレノキシンを含有する懸濁型水性液剤 - Google Patents

ピレノキシンを含有する懸濁型水性液剤 Download PDF

Info

Publication number
WO2008111630A1
WO2008111630A1 PCT/JP2008/054566 JP2008054566W WO2008111630A1 WO 2008111630 A1 WO2008111630 A1 WO 2008111630A1 JP 2008054566 W JP2008054566 W JP 2008054566W WO 2008111630 A1 WO2008111630 A1 WO 2008111630A1
Authority
WO
WIPO (PCT)
Prior art keywords
pirenoxine
type aqueous
aqueous preparation
containing suspension
suspension
Prior art date
Application number
PCT/JP2008/054566
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Asada
Seiji Yoshida
Nanoko Tsutimoto
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Priority to CN200880007992.3A priority Critical patent/CN101636163B/zh
Priority to KR1020097018762A priority patent/KR101519673B1/ko
Publication of WO2008111630A1 publication Critical patent/WO2008111630A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

 本発明は懸濁型水性液剤中のピレノキシンの容器への固着を抑制する。懸濁型水性液剤中にポリオキシエチレン硬化ヒマシ油及びトロメタモールからなる群より選択される少なくとも１種を含有することにより、ピレノキシンの容器への固着を抑制することができる。
PCT/JP2008/054566 2007-03-13 2008-03-13 ピレノキシンを含有する懸濁型水性液剤 WO2008111630A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200880007992.3A CN101636163B (zh) 2007-03-13 2008-03-13 含有吡诺克辛的混悬型水性液体制剂
KR1020097018762A KR101519673B1 (ko) 2007-03-13 2008-03-13 피레녹신을 함유하는 현탁형 수성 액제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007063787 2007-03-13
JP2007-063787 2007-03-13

Publications (1)

Publication Number Publication Date
WO2008111630A1 true WO2008111630A1 (ja) 2008-09-18

Family

ID=39759561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/054566 WO2008111630A1 (ja) 2007-03-13 2008-03-13 ピレノキシンを含有する懸濁型水性液剤

Country Status (5)

Country Link
JP (1) JP4958818B2 (ja)
KR (1) KR101519673B1 (ja)
CN (2) CN101636163B (ja)
TW (1) TWI465236B (ja)
WO (1) WO2008111630A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02164826A (ja) * 1988-12-20 1990-06-25 Taisho Pharmaceut Co Ltd トコフェロール類含有液剤
JPH04300830A (ja) * 1991-03-28 1992-10-23 Zeria Pharmaceut Co Ltd ビタミンｅ類の水溶液の製剤
JP2002003364A (ja) * 2000-06-23 2002-01-09 Lion Corp 点眼剤、眼科用組成物及び吸着抑制方法
JP2002161037A (ja) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd 点眼液
WO2006030851A1 (ja) * 2004-09-15 2006-03-23 Santen Pharmaceutical Co., Ltd. ピレノキシン懸濁型点眼剤
JP2007008928A (ja) * 2005-06-01 2007-01-18 Rohto Pharmaceut Co Ltd アシタザノラスト含有水性組成物
JP2007119422A (ja) * 2005-10-31 2007-05-17 Santen Pharmaceut Co Ltd 合成樹脂成形物に吸着しやすい薬物の吸着抑制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612537C1 (de) * 1986-04-14 1987-07-16 Dispersa Ag Arzneimittel zur Behandlung von Entzuendungen im Auge
DE3612538A1 (de) * 1986-04-14 1987-10-15 Dispersa Ag Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen
JPH0737386B2 (ja) * 1988-10-12 1995-04-26 参天製薬株式会社 懸濁型ピレノキシン点眼剤
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
WO2000059470A1 (fr) * 1999-04-05 2000-10-12 Senju Pharmaceutical Co., Ltd. Emulsion et son procede de production
JP2005154437A (ja) * 2003-11-07 2005-06-16 Rohto Pharmaceut Co Ltd トラニラスト含有医薬組成物
CN100362991C (zh) * 2004-06-02 2008-01-23 刘继东 一种眼科用药物组合物
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
WO2006049250A1 (ja) * 2004-11-05 2006-05-11 Senju Pharmaceutical Co., Ltd. 眼内移行性促進水性点眼剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02164826A (ja) * 1988-12-20 1990-06-25 Taisho Pharmaceut Co Ltd トコフェロール類含有液剤
JPH04300830A (ja) * 1991-03-28 1992-10-23 Zeria Pharmaceut Co Ltd ビタミンｅ類の水溶液の製剤
JP2002003364A (ja) * 2000-06-23 2002-01-09 Lion Corp 点眼剤、眼科用組成物及び吸着抑制方法
JP2002161037A (ja) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd 点眼液
WO2006030851A1 (ja) * 2004-09-15 2006-03-23 Santen Pharmaceutical Co., Ltd. ピレノキシン懸濁型点眼剤
JP2007008928A (ja) * 2005-06-01 2007-01-18 Rohto Pharmaceut Co Ltd アシタザノラスト含有水性組成物
JP2007119422A (ja) * 2005-10-31 2007-05-17 Santen Pharmaceut Co Ltd 合成樹脂成形物に吸着しやすい薬物の吸着抑制方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost

Also Published As

Publication number Publication date
JP4958818B2 (ja) 2012-06-20
KR20090118960A (ko) 2009-11-18
JP2008255111A (ja) 2008-10-23
CN101636163B (zh) 2015-07-08
TWI465236B (zh) 2014-12-21
TW200906415A (en) 2009-02-16
CN101636163A (zh) 2010-01-27
KR101519673B1 (ko) 2015-05-12
CN102716079B (zh) 2015-07-08
CN102716079A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
WO2007090393A3 (de) Pharmazeutische zubereitung auf basis vom mikrotabletten
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
EP1776225A4 (en) NANOSTRUCTURE POST-TREATMENT ENCODING: COMPOSITIONS, DEVICES AND SYSTEMS THEREWITH
WO2006127079A3 (en) A coated delivery system for active components as part of an edible composition
WO2010148000A3 (en) Dispenser adapted to engage a bottle and for use with consumable fluid having solid ingredients
WO2008026132A3 (en) Liquid dispenser with associated refill unit
WO2011081656A3 (en) Refill, adapter for a refill, and method of retaining a refill
WO2009121970A3 (de) Schichtmaterial
WO2011060363A3 (en) Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
WO2010052070A3 (en) Concentrated shampoo composition
IL200102A0 (en) 6-benzyl-3,3 dimethyl-2,3,4,7-tetrahydro-indolo{2,3-c} quinoline compounds, compositions containing the same and uses thereof
WO2010122332A3 (en) Xanthan gum and swellable particulate containing composition and uses thereof
WO2011107713A3 (fr) Nouvel agent pour améliorer le dépôt d'huile sur les cheveux
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
WO2008017957A3 (en) Devices containing lipid emulsions
WO2008123396A1 (ja) フルオロメトロンを含有する懸濁型点眼剤
WO2011110922A3 (en) Housing base and associated housing and assembly method
WO2008019782A3 (de) Dispersionen von nanoharnstoffen. enthaltend wirkstoffe
WO2009102707A3 (en) Substituted oxazaphosphorines
WO2007125521A3 (en) Polymorphic form of zoledronic acid and processes for their preparation
WO2008111630A1 (ja) ピレノキシンを含有する懸濁型水性液剤
GB2446267B (en) Imidazoline compounds and lubricating compositions containing the same
WO2009010298A8 (en) Paullone derivatives and its use
WO2007108817A3 (en) Alcoholic beverage dispensing system
USD645704S1 (en) Beverage container

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880007992.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721979

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097018762

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721979

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP